Tirzepatide Research Peptide — Buy Dual GLP-1/GIP Co-Agonist (≥97% Purity)
Tirzepatide (CAS 2023788-19-2) is a synthetic twincretin peptide that functions as a dual agonist at both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. As the first dual incretin co-agonist to demonstrate superior metabolic effects over GLP-1 monoagonism in clinical models, tirzepatide has become an essential research compound for studying incretin biology, metabolic disease, and adipose tissue regulation.
Mechanism of Action
Tirzepatide simultaneously activates GLP-1R and GIPR, two class B GPCRs with complementary roles in incretin-mediated insulin secretion. GIP receptor activation augments insulin response and promotes lipid metabolism and adipogenesis regulation — effects not observed with GLP-1R agonism alone. The dual mechanism produces additive or synergistic effects on glycemic control, fat mass reduction, and energy expenditure in preclinical models, making tirzepatide an invaluable tool for comparative receptor pathway research.
Research Applications
- Dual incretin receptor co-agonism and signaling studies
- Glucose homeostasis and insulin secretion models
- Lipid metabolism, adipogenesis, and adipose biology research
- Energy expenditure and body composition studies
- Comparative GLP-1 vs. GIP receptor pathway analysis
Specifications
- Chemical Name: Tirzepatide
- CAS Number: 2023788-19-2
- Molecular Weight: ~4,813 Da
- Purity: ≥97% (HPLC verified)
- Form: Lyophilized powder
- Available Sizes: 2mg, 5mg, 10mg
Storage & Handling
Store lyophilized tirzepatide at −20°C. Reconstitute with bacteriostatic water; store reconstituted solution at 4°C for up to 28 days. Avoid repeated freeze-thaw cycles. Handle under aseptic laboratory conditions.
For in-vitro laboratory research use only. Not for human or animal consumption. Not a drug, supplement, or medicinal product.
